(D341-0349)
1
Identification
| Name |
D341-0349
|
| Formula |
C21H17N3S
|
| MW |
343.44 |
| CAS No. |
|
| EINECS |
|
| Smiles |
C12SC=C(C3C=CC=CC=3)C1=C(N1CC3C=CC=CC=3CC1)N=CN=2 |
| Synonyms |
|
| InChI |
InChI=1S/C21H17N3S/c1-2-7-16(8-3-1)18-13-25-21-19(18)20(22-14-23-21)24-11-10-15-6-4-5-9-17(15)12-24/h1-9,13-14H,10-12H2 |
2
Introduction
D341-0349 is a novel cyclin-dependent kinase 8 (CDK8) inhibitor. The inhibition rate is 50.8±2.6% at 10 μM. CDK8 gene expression correlates with increased mortality in colorectal, breast, and ovarian cancers and its overexpression is essential for the proliferation of cancer cells. Due to its key roles in oncogenesis, CDK8 has recently attracted considerable attention. Inhibitors of CDK8 offer a novel strategy for the treatment of various cancers.
Background Information
3
Protocol(Only for Reference)
Cell Experiment
Animal Experiment
4
Physical and Chemical Properties
| Appearance: |
EBNumber:EB100692271 |
Storage condition
Solubility
5
Mechanism and Indication
6
Clinical Information
| Product Name |
Sponsor & Collaborators |
Indications |
Start Date |
End Date |
Phase |
7
Safety Data of D341-0349
9
Suppliers List
| Company |
Price and Availability |
Country/Region |
| AMEDCHEM |
|
CHINA |
10
Related Products
Other Forms of
Recommended Compounds in
CDK
Recommended Compounds in Same Indication
